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Abstract
Background: Matrix metalloproteinase (MMP) 14 may mediate tumor progression through vascular and immune-
modulatory effects.
Methods: Orthotopic murine breast tumors (4T1 and E0771 with high and low MMP14 expression, respectively; n = 5–10 per 
group) were treated with an anti-MMP14 inhibitory antibody (DX-2400), IgG control, fractionated radiation therapy, or their 
combination. We assessed primary tumor growth, transforming growth factor β (TGFβ) and inducible nitric oxide synthase 
(iNOS) expression, macrophage phenotype, and vascular parameters. A linear mixed model with repeated observations, 
with Mann-Whitney or analysis of variance with Bonferroni post hoc adjustment, was used to determine statistical 
significance. All statistical tests were two-sided.
Results: DX-2400 inhibited tumor growth compared with IgG control treatment, increased macrophage numbers, and 
shifted the macrophage phenotype towards antitumor M1-like. These effects were associated with a reduction in active 
TGFβ and SMAD2/3 signaling. DX-2400 also transiently increased iNOS expression and tumor perfusion, reduced tissue 
hypoxia (median % area: control, 20.2%, interquartile range (IQR) = 6.4%-38.9%; DX-2400: 1.2%, IQR = 0.2%-3.2%, P = .044), 
and synergistically enhanced radiation therapy (days to grow to 800 mm3: control, 12 days, IQR = 9–13 days; DX-2400 plus 
radiation, 29 days, IQR = 26–30 days, P < .001) in the 4T1 model. The selective iNOS inhibitor, 1400W, abolished the effects of 
DX-2400 on vessel perfusion and radiotherapy. On the other hand, DX-2400 was not capable of inducing iNOS expression or 
synergizing with radiation in E0771 tumors.
Conclusion: MMP14 blockade decreased immunosuppressive TGFβ, polarized macrophages to an antitumor phenotype, 
increased iNOS, and improved tumor perfusion, resulting in reduced primary tumor growth and enhanced response to 
radiation therapy, especially in high MMP14-expressing tumors.
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Matrix metalloproteinases (MMPs) facilitate cancer progression 
(1–3). However, broad-spectrum MMP inhibitors failed in part 
because MMPs mediate both pro- and anticancer effects (4–7) and 
because off-target, dose-limiting toxicity impeded efficacy (7). To 
counter these deficiencies, agents targeting specific MMPs have 
been developed. For breast cancer (BC), MMP14 (membrane type 
1-MMP; MT1-MMP) is an especially attractive target (2,8). Genetic 
knockdown of MMP14 in BC cells impedes their migration and 
metastases but does not affect their in vitro viability or primary 
tumor growth (3,8). In contrast, antibody inhibition—which blocks 
both cancer and stromal MMP14 activity—slows primary tumor 
growth (9,10). Indeed, a considerable number of reactive stromal 
cells also express MMP14 (2), illustrating the potential importance 
of stromal MMP14.
MMP14 facilitates angiogenesis (11–13), and MMP14 blockade 
can inhibit tumor angiogenesis (9,10). Various antiangiogenic 
agents, however, can also transiently normalize the tumor vas-
culature, improving tumor perfusion and oxygenation, leading 
to enhanced efficacy of chemo- and/or radiation-therapy (14–16). 
In preclinical models, blockade of MMP14 could enhance the 
response to cytotoxic therapies (9,10). These findings prompted 
us to determine a potential improvement in tumor vascular func-
tion by MMP14 blockade.
The antiangiogenic effect of MMP14 inhibition is thought to 
result from reduced activation of MMP2 by MMP14 (9). However, 
other MMP14 targets have not been studied, including transform-
ing growth factor β (TGFβ), a mediator of vascular response and a 
potent immunosuppressor. TGFβ is associated with poor clinical 
outcome in BC (17). TGFβ has proangiogenic activities and medi-
ates vessel stabilization (18–20). TGFβ inhibitors increase anti-
tumor immunity associated with increasing interferon (IFN)-γ 
and granzyme B production from natural killer (NK) cells and 
cytotoxic CD8+ T cells, reducing T regulatory cells, and shifting 
macrophages toward an inducible nitric oxide synthase (iNOS)–
expressing antitumor M1-like phenotype and away from tumor-
supportive M2-type (21–27).
In this study we investigated if DX-2400 (9), a highly selec-
tive MMP14 inhibitory antibody, could decrease TGFβ levels and 
alter the macrophage phenotype in tumors. We also aimed to 
determine if DX-2400 could improve tumor vessel function and 
thus provide additional benefits when combined with radiation 
therapy.
Methods
Tumor Models
All animal procedures followed Public Health Service Policy on 
Humane Care of Laboratory Animals guidelines and were approved 
by the Massachusetts General Hospital Institutional Animal Care 
and Use Committee. A single 4T1 primary tumor per mouse was 
established by implanting 1x105 cells into the third mammary 
fat pad (MFP). As previous studies using anti-MMP14 antibodies 
employed NU/NU (nude) mice (9,10), we also used female (age six 
to eight weeks) nude mice to assess if macrophages were capable 
of responding to DX-2400 in the absence of adaptive immunity. 
We then confirmed key findings in immunocompetent C57BL/6 
mice bearing syngenic E0771 tumors. E0771 tumors were estab-
lished by implanting 2x105 cells in the MFP of wild-type C57BL/6 
or NOS2-/- mice. For optical frequency domain imaging, an MFP 
window was fitted around 4T1 tumors of approximately 10 mm3 
in syngenic BALB/c mice age 10 to 12 weeks. Details are provided 
in Supplementary Methods (available online).
Treatments
Treatment began once primary tumors reached approximately 
40 mm3. Control IgG or DX-2400 was injected at an established 
effective dose (10 mg/kg) every 48 hours i.p. (9). Treatment con-
tinued for a maximum of 10 injections. Local radiotherapy began 
four days after tumors reached approximately 40 mm3 (ie, equiva-
lent to day 4 of DX-2400 or IgG treatment). Fractionated irradia-
tion was given using XRAD 320 irradiator (Precision X-Ray, Inc.) at 
3.5 Gy/min to a total dose of 6 Gy per daily fraction on three con-
secutive days. A selective iNOS inhibitor (1400W dihydrochloride, 
Enzo Life Sciences) was delivered by s.c. osmotic minipump (Alzet 
1002; 0.42 mg/kg/hour).
Immunostaining
Details are provided in the Supplementary Methods (available 
online). Primary antibodies included: MMP14, cluster differen-
tiation factor 31 (CD31, endothelial cell marker), NG2 (pericyte 
marker), Collagen IV (basement membrane (BM) marker), iNOS-
FITC, CA9 (hypoxia marker), HSP90, SMAD2/3, F4/80-Cy5 (mac-
rophage marker), mannose receptor C type 1 (MRC1, M2 marker), 
granzyme B (cytotoxic activity marker), NK1.1-Cy3 (NK cell 
marker), proliferating cell nuclear antigen (PCNA, proliferation 
marker), and Apoptag (apoptosis marker).
Optical Frequency-Domain Imaging
Optical Frequency-Domain Imaging (OFDI) allows detailed 
analysis of the geometry and functionality of the perfused 
tumor vasculature (28). OFDI was performed at day 4 using 
a custom-built microscope as described previously (28). 
Additional details are provided in the Supplementary Methods 
(available online).
Western Blotting and Antibody Array
Details are provided in the Supplementary Methods (available 
online). Protein was collected from tumors following six days of 
treatment. Primary antibodies included MMP14 (Abcam, ab51074, 
1:1000), iNOS (BD Biosciences, 610329, 1:500), TGFβ (Cell Signaling, 
3711S, 1:1000), and β-actin (Sigma, A5441, 1:5000). The antibody 
array (RayBiotech, AAM-INF-1) protocol followed manufacturer’s 
instructions.
Image Analysis
Details are provided in the Supplementary Methods (available 
online). Quantification of staining was performed using an in-
house MATLAB (MathWorks) segmentation algorithm or ImageJ 
(29). Relative densitometry was determined using ImageJ with 
normalization to the loading control.
Statistical Methods
PRISM (GraphPad Software, version 6e) and Statistical Analysis 
System (SAS) 9.4 were used for analyses. All statistical analy-
ses between two groups were performed using the nonpara-
metric Mann-Whitney test. However, when more than two 
groups were assessed, following confirmation that normal-
ity was achieved (using Kolmogorov-Smirnov test in PRISM), 
data were assessed by analysis of variance (ANOVA) followed 
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by Bonferroni adjusted post hoc t tests for multiple pairs of 
interest without a priori selection. Robust regression and out-
lier removal (ROUT, GraphPad) was used to determine if outli-
ers were present. All statistical tests were two-sided. A mixed 
model was fitted to test the differences between treatment and 
control tumor growth curves accounting for repeated measure-
ments over time and mouse as a random effect. Differences 
were considered statistically significant at P values of less than 
.05; P values between .05 and .1 were considered to show a trend 
and are also presented in figures. Data are presented as median 
with the interquartile range and, in the case of boxplots and 
column graphs, maximum and minimum values.
Results
MMP14 Expression in Murine BC Models
We determined MMP14 protein expression in 4T1 and E0771 BC 
cells in in vitro culture and in tumor tissues in vivo (Figure 1A). 
Although MMP14 protein was detected in both BC models, 
4T1 tumors express a notably higher level of MMP14 com-
pared with E0771. We confirmed that MMP14 was membrane 
associated in these models (Figure 1B). We then costained for 
MMP14 and F4/80 and discovered that essentially every mac-
rophage expressed MMP14 (Figure  1, C and D), thus showing 
that MMP14 may not be differentially expressed by M1- and 
M2-type macrophages.
Efficacy of anti-MMP14 antibody (DX-2400) in vivo and in 
vitro. We confirmed that DX-2400 treatment reduced collageno-
lytic activity, a readout of MMP14 activity, in 4T1 tumors effec-
tively in vivo (P = .0457) (Figure 1, E and F). We also confirmed that 
DX-2400 treatment of 4T1 cells in vitro did not affect cell viability 
(Figure 1G), but it statistically significantly inhibited cell invasion 
through a collagen matrix in a dose-dependent manner (P = .0314 
with DX-2400 at 0.2  µg/mL to P  =  .0004 following DX-2400 at 
100 µg/mL treatment) (Figure 1H).
Effect of Anti-MMP14 Treatment on BC Growth
Monotherapy with the anti-MMP14 antibody (DX-2400) statisti-
cally significantly delayed both 4T1 and E0771 tumor growth. 
A  mixed model indicated a statistically significant reduction 
in tumor growth rate following DX-2400 treatment in both 
tumor models (P < .001 for both models) (Figure  2, A and B; 
Supplementary Figure 1, A and B, available online). Subsequent 
analysis of each individual time point indicated that this diver-
gence in tumor growth was statistically significant from day 6 
onwards (4T1, P  =  .0028, CT 279.9 mm3 ± 117.7, DX 128.4 mm3 ± 
51.2; E0771, P =  .017, CT 144.9 mm3 ± 57.4, DX 78.14 mm3 ± 46.5; 
mean ± SD). Consistent with reduced 4T1 growth, there was 
a trend for increased apoptosis at day 4 and necrosis at day 
10 (P  =  .0606 and P  =  .0590) (Figure  2, C and D; Supplementary 
Figure 2, A and B, available online). Although apoptosis at day 4 
was not statistically significantly reduced, zero out of five control 
IgG–treated tumors were found to have a high frequency of apop-
tosis (Figure 2C) while four out of six DX-2400–treated tumors had 
areas of high apoptotic rates. Thus, the lack of significance could 
reflect the small sample size. Proliferation was statistically sig-
nificantly inhibited at day 4 (P = .0411, CT 1113 proliferative cells/
FoV [interquartile range {IQR} = 973–1182], DX 908 [IQR = 686–988], 
median [lower quartiles to higher quartiles]) with a trend towards 
decreased proliferation at day 10 (P  =  .093) (Figure  2, E and F; 
Supplementary Figure 2, C and D, available online).
Effect of MMP14 Blockade on Tumor-Associated 
Macrophages
Given the early (day 4) reduction in proliferation and subsequent 
tumor growth delay, we aimed to determine if the tumor micro-
environment was also altered by treatment at this stage. In 4T1 
BC, DX-2400 led to a modest increase in F4/80+ cell numbers at 
day 4 (P =  .0148, CT 0.100 staining area/DAPI area [IQR = 0.03–
0.27], DX 0.339 [IQR = 0.23–0.45]) and a dramatic increase in the 
proportion of macrophages expressing iNOS (an M1 marker) 
(P =  .0003, CT 0.004 area colocalization [IQR = 0.001–0.005], DX 
0.140 [IQR  =  0.066–0.256]) (Figure  3, A and B). We also exam-
ined markers of cytotoxic activity (granzyme B) and M2 phe-
notype (MRC1). Granzyme B, typically expressed by NK cells in 
nude mice, was substantially increased by DX-2400 (P =  .0012, 
CT 0.006 staining area/DAPI area [IQR  =  0.0008–0.0316], DX 
0.087 [IQR  =  0.0374–0.1456]) (Figure  3C). Some macrophages 
also expressed granzyme B, and this was higher in DX-2400–
treated tumors (P =  .0005) (Supplementary Figure 3, A-C, avail-
able online). Moreover, we found that granzyme B–positive cells 
associated more frequently with F4/80+ cells in DX-2400–treated 
tumors (P = .0005) (Supplementary Figure 3, A and D). In contrast 
to M1-type markers, DX-2400 reduced MRC1 positivity (P = .0111, 
CT 0.008 area colocalization [IQR  =  0.007–0.025], DX 0.003 
[IQR = 0.0008–0.0065]) (Figure 3D). We also found that active TGFβ 
and its downstream signaling partner SMAD2/3 were reduced in 
4T1 tumors by DX-2400 treatment (P = .0011) (Figure 3, F and G). 
In vitro, we saw that macrophages treated with TGFβ decreased 
expression of the M1 marker iNOS (Supplementary Figure  4A, 
available online). Supporting a shift in macrophage response, we 
used an antibody array to provide an indication of the broader 
cytokine profile of tumors. We found that IFNγ and GM-CSF (M1 
associated cytokines) were generally higher in DX-2400–treated 
tumors, while interleukin (IL)-4, IL-10, and G-CSF (M2-type 
responses) were generally lower following DX-2400 treatment 
(Supplementary Figure 4B, available online). Furthermore, NK cell 
numbers increased with DX-2400 in 4T1 tumors (Supplementary 
Figure  4, C and D). Statistically significant changes were also 
seen in E0771 tumors, such as the increase in F4/80+ (P = .0260, 
CT 0.064 staining/DAPI [IQR = 0.04–0.13], DX 0.171 [IQR = 0.11–
0.26]) (Figure 3H) and iNOS+F4/80+ (P = .0022, CT 0.005 area colo-
calization [IQR  =  0.0005–0.0133], DX 0.047 [IQR  =  0.022–0.068]) 
(Figure  3I), as well as granzyme B+ cells, NK cells, and gran-
zyme B+ NK cells (Supplementary Figure 4, E-I, available online). 
Similarly, the proportion of M1-type macrophages increased in 
DX-2400–treated 4T1 tumors grown in syngeneic BALB/c mice 
(Supplementary Figure  4J, available online). Collectively, we 
found that MMP14 blockade shifts immune cell and cytokine 
profiles from immunosuppressive to antitumor phenotype in 
our BC models.
Effect of MMP14 Inhibition on BC iNOS Expression
While assessing iNOS as an M1 marker, we also noted a statisti-
cally significant increase in gross tumor-associated iNOS in the 
4T1 tumors following DX-2400 treatment (P  =  .0095, CT 0.005 
staining/DAPI [IQR  =  0.002–0.008], DX 0.013 [IQR  =  0.007–0.019]) 
(Figure 4A-C; Supplementary Figure 5A, available online). On the 
other hand, baseline iNOS was approximately seven-fold higher 
in the E0771 model compared with the 4T1 model (CT 0.028 
staining/DAPI [IQR  =  0.012–0.061], DX 0.057 [IQR  =  0.026–0.153]) 
(Figure  4, C and D; Supplementary Figure  6, available online), 
which may have limited the ability of DX-2400 to further increase 
iNOS levels in this tumor model. In 4T1 tumors, we also found 
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Figure 1. MMP14 expression and activity in breast cancer in vivo and its direct effects on tumor cells in vitro. A) Western blot of MMP14 in 4T1 and E0771 cell lines and 
tumors grown orthotopically in the mammary fat pad of nude or C57BL6 mice, respectively. Blots exposed for one minute or five minutes for MMP14 and one minute for 
β-actin. B-D) Immunofluorescence staining for MMP14 in 4T1 tumors. MMP14 was broadly expressed within the tumor (B) and showed bright staining on macrophages 
(F4/80 marker) (C-D). All macrophages appeared to express MMP14; ie, no red single staining cells, only yellow colocalization visible (C, higher magnification; D, lower 
magnification). E-F) Collagenolytic activity decreased following treatment with DX-2400 (10 mg/kg). Representative DQ-collagen type I images; control (E) and quanti-
fication (relative fluorescence units) of collagenolytic activity (DQ-collagen type-I) (F). G) Data from five replicates are shown. The effect of DX-2400 concentration (µg/
mL) on 4T1 cell viability (inset, E0771 cells treated with 50 µM DX-2400) expressed as relative luminescence units. BC cell viability was unaffected by DX-2400 at the 
concentrations of 0.1–50 µg/mL. E0771 cell data in the inset was P = 0.1. Here, day 3 data are presented. Day 1 and 2 data were similar. H) Data from three replicates 
are shown. The effect of DX-2400 concentration (µg/mL) on 4T1 cell invasion. In contrast to cell viability, cell invasion through collagen I was statistically significantly 
reduced by DX-2400 at all concentrations tested (0.2–100 µg/mL). F-H) Data are presented as median with the interquartile range (box and whiskers). P values are 
shown. Analysis of invasion and viability were performed in triplicate, n > 7 for DQ collagen analysis. Statistical significance determined by two-sided Mann-Whitney 
test for DQ analysis and analysis of variance with Tukey’s correction. CT = control; DX = DX-2400; RLU = relative luminescence unit.
E.I. Ager et al. | 5 of 12
a
r
t
ic
le
a statistically significant increase in the colocalization of HSP90 
(normally degraded by MMP2 [30]) with iNOS in DX-2400–treated 
tumors at day 4 (CT 0.11 colocalization area [IQR = 0.03-0.024], DX 
0.31 [IQR = 0.19–0.49], P =  .0205) (Figure 4, E and F). HSP90 is an 
enhancer and essential cofactor of iNOS (31,32) and presumably 
facilitates increased iNOS levels in 4T1. Moreover, the increase in 
IFNγ seen in the antibody array could also increase tumor iNOS 
expression (33,34).
Effect of Anti-MMP14 Antibody Treatment on Tumor 
Vasculature
To investigate DX-2400–associated changes in the tumor vas-
cular geometry and function, we used a robust noninvasive 
imaging technique, OFDI, which specifically visualizes per-
fused (containing moving red blood cells) vessels. We found 
a statistically significant increase in the total number of per-
fused vessels with DX-2400 treatment (P = .0205, CT 73 vessels/
volume [IQR = 60–155], DX 196 [IQR = 165–385]) (Figure 5, A and B; 
Supplementary Figure 7, available online). Reasoning that NO is 
a vasodilator (35,36), we assessed vessel diameter. We confirmed 
fewer small-diameter vessels (less than 15  μm) in DX-2400–
treated 4T1 tumors (P = .0210) (Figure 5C). Additionally, DX-2400 
reduced the maximum tortuosity of vessels (P  =  .0460, CT 30 
tortuosity index [IQR  =  12–46], DX 10 [IQR  =  6–12]) (Figure  5D). 
Histological analyses of tumors collected after four to 10 days of 
treatment revealed no notable change in vessel (CD31) staining, 
while vessel maturity (pericyte coverage) was improved in 4T1 
tumors, although only on day 10 (Supplementary Figure 8, availa-
ble online). These results suggest that the antiangiogenic effects 
of MMP14 inhibition shown by others (9,10) may occur only after 
extended treatment, with higher doses (30 mg/kg Devy et al. (9) 
compared with 10 mg/kg used here), or are model specific. This 
is also consistent with previous findings that the dose of anti-
VEGFR2 treatment induces different effects on vasculature (37). 
We also assessed functionality of these vessels in tissue sections 
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Figure 2. Inhibition of 4T1 and E0771 tumor growth by MMP14 blockade. Mice were treated with control IgG (CT) or DX-2400 (DX) (10 mg/kg every 48 hours, up to 10 
injections) once tumors reached approximately 40 mm3 (day 0) to day 10, at which time mice were killed. A-B) Tumor growth curves. Data for 4T1 in nude (A) and 
E0771 in C57BL6 (B) are presented as median and interquartile range. Individual tumor growth curves are provided in Supplementary Figure 1 (available online). Tumor 
growth rates were statistically significantly different according to a mixed model analysis. C-D) Cell death. There was a trend towards increased apoptosis with DX-2400 
treatment at day 4 (C; high-frequency Apoptag staining assessed as greater than 10 apoptotic cells per field of view) and, similarly, necrosis tended to be greater in 
day 10 samples from DX-2400 treated animals. E-F) Cell proliferation. Day 4 proliferation (proliferating cell nuclear antigen) was decreased by DX-2400 (E), while day 
10 proliferation showed a trend (F). Images of Apoptag, necrosis, and PCNA are provided in Supplementary Figure 2 (available online). All data from panels C to F were 
obtained from 4T1 tumors in nude mice. Data are presented as median with the interquartile range (box) and maximum and minimum values (whiskers) for panels C 
to F. P values determined by two-sided Mann-Whitney test. Samples sizes: n = 6 for all analyses except day 10 necrosis (n > 8) and tumor growth curves (n = 10 for 4T1 
and n = 7 for E0771). CT = control; DX = DX-2400; FoV = field of view; HI = high-frequency; PCNA = proliferating cell nuclear antigen.
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Figure 3. Effect of anti-MMP14 treatment on F4/80+ macrophages and M1-like state. A-G) Data and representative images from day 4 4T1 tumors in nude mice except 
western blot of TGFβ (F, day 6). Both total F4/80+ area (A) and the area costaining with iNOS (an M1 marker) (B) were increased by DX-2400 (DX) treatment compared 
with control (CT). Granzyme B (cytotoxic activity) also increased with treatment (C), while MRC1 (an M2 marker) (D) decreased following DX-2400 treatment. E) Repre-
sentative images of stains. The stain performed is indicated at the top left of each CT image with the matched DX to the right. A scale bar is presented on the bottom 
right and is the same for all images (50 μm). F) A Western blot confirmed a decrease in active TGFβ (molecular weight ~25 KDa). G) DX decreased nuclear localization 
of SMAD2/3, downstream of TGFβ activation. H-I) Data from day 4 E0771 tumors in C57BL6 mice. An increase in total macrophages (H) and iNOS-expressing M1 mac-
rophages (I) for E0771 tumors confirmed results from the 4T1 model. Data are presented as median with the interquartile range (box) and maximum and minimum 
values (whiskers). Statistical significance determined by two-sided Mann-Whitney test; n = 8 for all analysis of 4T1 samples, and n = 6 for E0771 samples. Additional 
associated images and data are provided in Supplementary Figures 3 and 4 (available online). CT = control; DX = DX-2400.
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using trichrome staining (P = .0218, CT 0.6 perfused vessels/field 
of view [IQR = 0.42–0.67], DX 2.2 [IQR = 1.8–3]) (Figure 5E) and a 
vessel tracer Hoechst (Supplementary Figure 9, available online) 
and confirmed the OFDI findings—increased perfusion with 
DX-2400 treatment. Further, hypoxia, assessed by CA9 staining 
was also reduced by DX-2400 in 4T1 tumors (median % area: con-
trol, 20.2% [IQR = 6.4%-38.9%]; DX-2400: 1.2% [IQR = 0.2%-3.2%], 
P =  .044) (Figure 5F; Supplementary Figure 10, available online). 
NO, a potent vasodilator, is an important regulator of vessel 
function (38). The increase in vessel diameter without changes 
in the number of endothelial cells (CD31 positivity) suggests that 
functional vessel dilatation rather than hyper proliferation plays 
a key role in vessel diameter increase in this setting. Indeed, 
blockade of iNOS (by 1400W) prevented the DX-2400–induced 
improvement in perfusion and oxygenation (Figure 5, E and F). 
In E0771 tumors there was no statistically significant difference 
in hypoxia between DX-2400 and control (Figure  5G), possibly 
reflecting the lack of increased tumor iNOS in this model.
Effect of MMP14 Blockade and Radiation Combined 
Treatment
Radiation therapy, similar to DX-2400, delayed 4T1 tumor growth 
compared with control (days to grow to 800 mm3: control, 12 days 
[IQR = 9–13 days]; DX, 19 days [IQR = 18–20 days]; R, 17.5 days 
[IQR  =  16–20  days]; and DXRDX, 29  days [IQR  =  26–30  days], P 
≤ .001) (Figure 6, A and B; Supplementary Figure 11A, available 
online). The combination therapy resulted in superior growth 
inhibition compared with either monotherapy (P ≤ .0001), and 
this effect was greater than the expected additive effect (P = .054, 
and, confirmed in Figure  6F, P  =  .042), demonstrating synergy 
between these therapies. In E0771 tumors, identical radiation 
and DX-2400 treatments were also effective, but their com-
bination led to an additive tumor growth delay only (P =  .430) 
(Figure 6, C and D; Supplementary Figure 11B, available online).
To understand when DX-2400 and irradiation treatments inter-
act and if this correlated with day 4 changes in tumor perfusion 
Figure 4. Effect of MMP14 inhibition on iNOS expression in 4T1 tumors. A-C) Immunofluorescence staining of iNOS in 4T1 (A & B, representative images of control 
[CT] and DX-2400 [DX] treatment, respectively) revealed an increase with DX-2400 treatment at day 4 in 4T1 tumors (B). iNOS levels were not statistically significantly 
changed by DX-2400 treatment in the E0771 tumor model (D). E-F) HSP90 and iNOS expression. E) Representative images of HSP90 and iNOS immunofluorescent stains). 
HSP90, an essential cofactor and activator of iNOS, colocalization with iNOS also statistically significantly increased in the 4T1 tumor model (F). Scale bars are pre-
sented in the bottom right of each DX image and are the same for CT and DX images. Data are presented as median with the interquartile range (box) and maximum 
and minimum values (whiskers); n = 6 for E0771 samples, and n = 10 for 4T1 iNOS analysis, and n = 7 for HSP90+iNOS analysis. Statistical significance determined by 
two-sided Mann-Whitney test. Additional associated images and data are provided in Supplementary Figures 5 and 6 (available online). Note: y-axis scales in panels A 
and C are optimized for each tumor model. CT = control; DX = DX-2400.
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and oxygenation, we compared the efficacies of three combina-
tion strategies: 1)  as above, 10 DX-2400 injections over 20  days 
before, during, and after irradiation (DXRDX), 2)  three antibody 
injections beginning at day 0 and extending to day 4 when the 
first fraction of irradiation was given (DX_R), or 3) seven postir-
radiation injections (R_DX). Pretreatment with DX-2400 essen-
tially replicated the benefit seen in the DXRDX group (Figure 6E; 
Supplementary Figure  11C, available online). In contrast, the 
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Figure 5. Effect of DX-2400 and iNOS blockade on perfusion and hypoxia in the 4T1 tumor model. A) Representative optical frequency domain images (OFDI) of control 
(CT)- and DX-2400 (DX)–treated tumors. B-E) Analyses of vascular parameters. The number of perfused vessels was increased by DX-2400 (B), while the frequency of 
vessels with a diameter of less than 15 μm was decreased by DX-2400 (C). The maximum tortuosity of vessels was also decreased by DX-2400 (D). Perfusion, assessed 
on trichrome stained tumor sections, was confirmed to increase with DX-2400 treatment, while blockade of iNOS with 1400W (DXW) prevented the DX-2400–associated 
increase in perfusion (E). F-G) Assessment of hypoxia. DX-2400 alone was also seen to decrease staining of CA9 (a marker of hypoxia), while the addition of 1400W to 
DX-2400 prevented this decrease (F). Contrary to the 4T1 model (A-F), the E0771 tumor model did not show a decrease in hypoxia with DX-2400 treatment (G). All data 
are from day 4 after treatment initiation. Data are presented as median with the interquartile range (box) and maximum and minimum values (whiskers). Sample size: 
n = 7 for OFDI analyses, n = 5 or 6 for all other analyses (ie, panels E-G). P values determined by two-sided Mann-Whitney test for B-D and G and by Kruskal-Wallis test 
for E and H. Additional associated images and data are provided in Supplementary Figures 7–10 (available online). Note: y-axis scales in panels F and G are optimized 
for each tumor model. CT = control; DX = DX-2400; DXW = 1400W in addition to DX; FoV = field of view.
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postirradiation treatment protocol did not result in a statistically 
significant tumor growth delay compared with irradiation alone 
and was statistically significantly worse (P  =  .026, R 14.5  days 
[IQR = 13–17], DXRDX 25 [IQR = 21–26], DX_R 23 [IQR = 21.5–26], and 
R_DX 19 [IQR = 15–21]) than the standard combination. Thus, the 
relatively short “priming” of tumors by DX-2400 treatment before 
irradiation appears critical for their synergism.
Blockade of iNOS by 1400W in 4T1 tumors (Figure  6F) or 
1400W or genetic knockout in NOS2-/- mice in E0771 tumors did 
not alter the efficacy of DX-2400 monotherapy (Supplementary 
Figure  11, E and F, available online), suggesting that iNOS and 
presumably its effects on vessels do not contribute to the tumor 
growth delay induced by DX-2400 alone. However, the addition of 
1400W to the combined DX-2400–radiation therapy was associ-
ated with a stimulation of tumor growth, ie, a loss of efficacy and 
synergy, compared with this combined therapy alone (P = 0.036, 
RDX 28 [IQR  =  26.5–30.5], RDXW 24 [IQR  =  22–26]) (Figure  6F; 
Supplementary Figure  11D, available online), suggesting that 
iNOS contributes to the tumor growth delay benefit of adding 
radiation to DX-2400. These findings are consistent with the abro-
gation by 1400W of effects of DX-2400 on tumor perfusion and 
oxygenation (Figure 5, E and F).
The P values presented in Figure  6 were determined using 
ANOVA with Bonferroni adjustment (as the variables of inter-
est fit the required normality assumption). It is worth noting 
that a Kruskal-Wallis analysis confirmed key findings: statisti-
cally significant reduction in tumor growth with DX-2400 (in 
the 4T1 model; P  =  .0243), statistically significant reduction in 
tumor growth upon combination treatment (in both models; 4T1 
P < .0001, E0771 P = .0012), a statistically significant reduction in 
tumor growth compared with radiation alone only when DX-2400 
was given before/during radiation (P  =  .0051 and .0037, respec-
tively) but not after radiation (P = .8865), and reduced efficacy of 
the combination therapy when iNOS was blocked (tumor growth 
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Figure 6. The effect of anti-MMP14, radiation, and their combination on BC models. A-D) The combination of DX-2400 and radiation is modestly synergistic in the 4T1 
tumor model and additive in the E0771 tumor model. Tumor growth curves for 4T1 tumors (A) and E0771tumors (C) in mice treated with control (CT), DX-2400 (DX), local 
fractionated irradiation (R; days 4, 5, and 6), or their combination (DXRDX). Mice were maintained and tumors measured until tumors reached approximately 1000 mm3 
or until morbidity was evident. Data are presented as median and interquartile range (panels A and C) with individual curves presented in Supplementary Figure 11 
(available online). All other data are presented as median with the interquartile range (box) and maximum and minimum values (whiskers). Sample size: n = 6 for 4T1 
and n = 4 or 5 for E0771. The time (days) taken for tumors to grow to 800 mm3 was used to assess tumor growth delay (panels B, 4T1, and D, E0771). The combination 
of DX-2400 and radiation was synergistic in the 4T1 model (B; expected additive range of DX+R is shown as horizontal dashed lines), while the combination was addi-
tive in the E0771 model (D). E) The effects of the timing of MMP14 inhibition. Ten DX-2400 injections (DXRDX) compared with three initial injections of DX-2400 (DXR; 
DX on days 0, 2, and 4 with radiation on days 4, 5, and 6) and seven postirradiation injections (RDX). F) The effects of iNOS were assessed using 1400W in addition to 
DX (DXW), radiation (RW), and the combination (DXRDXW). The synergy associated with combination treatment in the 4T1 model was lost when iNOS was inhibited. 
Analysis of variance with Bonferroni post hoc t test was performed for analysis of tumor growth. All statistical tests were two-sided. Additional data are provided in 
Supplementary Figure 11 (available online). CT = control; DX = DX-2400; DXR = three initial injections of DX-2400 plus radiation; DXRDX = ten DX-2400 injections plus 
radiation; DXRDXW = combination DXRDX plus 1400W; DXW = DX-2400 plus 1400W; RDX = radiation followed by DX-2400; RW = radiation plus 1400W.
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reduction compared with control; P  =  .0001 for RDX compared 
with P = .0012 for RDXW).
Discussion
Here, we show that the treatment with highly selective MMP14 
inhibitory antibody, DX-2400, was associated with the decrease in 
active TGFβ—an immunosuppressive cytokine—in murine BC tis-
sue. Consistent with this, macrophages were shifted towards antitu-
mor phenotype. Furthermore, we found that DX-2400 can increase 
vascular perfusion and reduce hypoxia in murine BC, resulting in 
synergistic therapeutic effectiveness of DX-2400 combined with 
radiation. We also found that iNOS appears to mediate these benefi-
cial effects of MMP14 blockade in combination with radiation.
Inhibition of MMP14 has antiangiogenic effects when exam-
ined at late stages of tumor development (9,10). However, we 
show that vascular responses differ at earlier time points. Our 
findings demonstrate improved vascular function at day 4 follow-
ing MMP14 inhibition that seems to be achieved through a reduc-
tion in vessel tortuosity and an increase in vessel diameter. We 
confirmed previous findings that antibody inhibition of MMP14 
can slow primary tumor growth (9,10), suggesting that an antian-
giogenic response is not required for the initial growth retarda-
tion from MMP14 inhibition, although it may contribute at later 
stages.
Typically, tumor-associated macrophages are polarized 
towards an M2-like state and provide support for tumor growth 
and progression (27,39). Consistent with the decrease in TGFβ, 
we discovered that DX-2400 induced M1-like macrophages that 
could contribute to primary tumor growth delay. We found that 
proliferation was reduced and necrosis increased. Activated NK 
cells can control tumor growth by inhibiting cellular proliferation 
and promoting apoptosis (40,41). TGFβ produced in the tumor 
stroma, however, leads to impaired NK cell function (40,42). In 
concordance with the reduction in TGFβ following DX-2400 treat-
ment, we showed an increase in NK cells and granzyme B produc-
tion with DX-2400.
The DX-2400–associated increase in iNOS at day 4 allied with 
an increase in vessel perfusion and a reduction in tumor hypoxia 
in the 4T1 model. Further, iNOS blockade prevented these vascu-
lar changes and resulted in the loss of synergy in combination 
with radiation. In the E0771 model, while macrophage numbers 
and macrophage-associated iNOS increased, tumor-wide iNOS 
expression and hypoxia were not substantially affected. This 
difference in response to DX-2400 is consistent with the failure 
of combination therapy to result in a more than additive ben-
efit in the E0771 model but may also reflect differences in the 
power to assess these differences because of the reduced sam-
ple size of E0771 compared with the study using 4T1 tumors. 
The sample sizes chosen were based on tumor growth curves 
from earlier studies using these models and a preliminary study 
using DX-2400, but the strength of our conclusions would have 
benefited from additional animals at early time points in the 
4T1 model and in studies using E0771 tumors. Biologically, 4T1 
and E0771 tumors differ in several respects, including endog-
enous MMP14 and iNOS expression, and altered response to 
DX-2400 could also reflect a combination of these differences. 
Moreover, the control tumors also differ considerably in their 
microvascular densities (Supplementary Figure  12, available 
online). Extravascular components are also important indirect 
regulators of vessel perfusion in solid tumors (43–45). Reduction 
in solid stress, such as by tumor cell death, could open non-
functional vessels and markedly increase tumor perfusion (44). 
Another potential mechanism by which DX-2400 could increase 
Figure 7. A schematic representation of the effects of MMP14 inhibition by DX-2400 in 4T1 primary breast tumors in nude mice. Pathways in gray are decreased by 
DX-2400 and those in black are increased. Red arrows show potential implications for monotherapy and combination therapies. DX-2400 increases vessel perfusion 
and tumor oxygenation; this is associated with an increase in iNOS expression in the tumor and coincides with an increase in HSP90. DX-2400 treatment also decreased 
vessel tortuosity, which possibly contributes to improved vessel perfusion. Improved perfusion led to an increase in the efficacy of radiation therapy. DX-2400 reduces 
TGFβ as well as M2-associated cytokine IL4 and the M2 marker MRC1, while it increases IFNγ, granzyme B, and iNOS—all markers of antitumor immune activity. A shift 
towards antitumor immune activity could contribute to the tumor growth delay seen earlier than the previously documented antiangiogenic effects. BM = basement 
membrane; CT = control; DX = DX-2400; NK = natural killer; RBC = red blood cell.
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tissue oxygenation is through decreased oxygen consumption 
by cancer cells, an effect that iNOS could also mediate (46).
Although radiation therapy is not widely used in the neo-
adjuvant setting for BC, we utilized it here for two reasons: 1) to 
evaluate the potential usefulness of MMP14 inhibition in other 
tumors for which radiation is more commonly utilized, and 2) to 
use radiation as an additional tool to evaluate DX-2400–induced 
changes in tumor oxygenation. The data obtained fulfill both pur-
poses. The synergistic tumor growth delay achieved in the 4T1 
model was modest, however. This is consistent with the relatively 
low average hypoxic fraction in control 4T1 tumors, approximat-
ley 20% at day 4 by CA9 staining fraction. Given that a dose of 6 
Gy of irradiation can kill approximately 70% of oxygenated 4T1 
clonogenic cells in vitro (47), each 6 Gy fraction used here would 
only eliminate aproximately 55% to 60% of all clonogenic 4T1 
cells, and so even converting all hypoxic cells to oxygenated cells 
before irradiation would only decrease the survival fraction by a 
further 10% to 15%. Higher doses of radiation per fraction and/
or lower tumor oxygenation (ie, more hypoxic tumors) might be 
expected to result in greater synergy.
Inhibition of MMP14 slowed growth of BC in orthotopic 
murine models and improved their response to concurrent radia-
tion therapy via improved tissue oxygenation (Figure 7). We found 
a novel association between antibody inhibition of MMP14 and 
an antitumor shift in macrophages and tumor immunity that 
could contribute to tumor growth delay resulting from anti-
MMP14 monotherapy. Moreover, the increase in MMP14 block-
ade–induced tumor iNOS led to improved vascular function and 
tissue oxygenation resulting in enhanced radiation response. 
These findings suggest MMP14 as a potential therapeutic target 
to modulate the tumor microenvironment and iNOS induction as 
a potential biomarker.
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